Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 The Alberta Diet: Effectiveness Study
Type 2 Diabetes
Primary: Change in Total Energy Intake — -178 kcal
Phase 2 N=22 Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs With CALGB-ECTC Grade 3 or 4, TEAEs Leading to Discontinuation, TEAEs Leading…
Phase 2 N=907 An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
Systolic Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -20.89; -23.55; -21.26; -19.31 mmHg
Phase 2 N=30 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Phase 2 N=47 A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Rheumatoid Arthritis
Primary: Percentage of Participants With Any Infusion Reaction — 13.6; 12.0 Percentage of Participants
Phase 2 N=141 Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in One Second (FEV1) Response [L] After Four Weeks of Treatment. — 0.057; 0.055 Litres — p=0.8937
Phase 2 N=33 BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Response Rate — 11 participants
Phase 2 N=60 A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
Ulcerative Colitis
Primary: Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT — 8; 8 Participants — p=0.7532
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
Phase 2 N=38 Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Pancreatic Neoplasms · Adenocarcinoma
Primary: Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation — 28; 14 percent of patients with PFS
Phase 2 N=59 Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
Intubated and Mechanically Ventilated Pediatric Subjects
Primary: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) — 2681.332; 6460.576; 16992.540; 28531.864 picograms*hr/mL
Phase 2 N=60 FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions. — 100 Percentage of Participants
Phase 2 N=360 Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 Response [L] After 4 Weeks of Treatment — 0.110; 0.134; 0.143; 0.168 L — p=0.3791